Table 4.

Results of sensitivity analyses assuming lower sensitivity and higher specificity for CBE, and assuming an alternative treatment distribution. Costs and QALYs are discounted at 3%. Dominated strategies are indicated with ’—’

Assuming lower sensitivity and higher specificity for CBE					Assuming alternative survival model
Strat	Total Cost ($)	QALYs (years)	Incremental QALYs gained	ICER	Strat	Total Cost ($)	QALYs (years)	Incremental QALYs gained	ICER
X	13,100	27.3944			X	13,000	27.4158
B	14,300	27.4239	—	—	A	14,300	27.4427	0.0270	46,900
A	14,300	27.4265	0.0321	36,900	B	14,300	27.4396	—	—
D	14,700	27.4288	—	—	C	14,600	27.4448	0.0021	152,100
C	14,700	27.4331	0.0067	58,600	D	14,700	27.4450	—	—
E	14,900	27.4317	—	—	E	15,000	27.4449	—	—
F	15,100	27.4335	—	—	F	15,200	27.4459	—	—
G	15,100	27.4345	—	—	G	15,200	27.4466	0.0018	339,400
H	15,300	27.4357	—	—	H	15,300	27.4465	—	—
I	15,400	27.4359	0.0028	250,200	I	15,500	27.4470	0.0005	611,800
J	20,800	27.4376	0.0016	3,293,300	J	21,000	27.4480	0.0009	5,847,100

MM=Mammography; CBE=Clinical breast exam; intv=time interval between examinations (in years)

Total Cost: Mean total cost per woman in the complete cohort, rounded to the nearest $100

QALYs: Mean total expected quality-adjusted life years per woman from age 20 in the complete cohort

ICER: Incremental cost-effectiveness ratio (incremental cost/incremental QALYs gained compared to next least-expensive strategy)

Current recommended strategies are shown in boldface: A=NCI/USPSTF; C=NCI; I=NCI/USPSTF; J=ACS